9.50Open9.50Pre Close0 Volume110 Open Interest2.00Strike Price0.00Turnover740.12%IV9.94%PremiumJan 17, 2025Expiry Date8.46Intrinsic Value100Multiplier22DDays to Expiry1.04Extrinsic Value100Contract SizeAmericanOptions Type0.9657Delta0.0040Gamma1.15Leverage Ratio-0.0334Theta0.0006Rho1.11Eff Leverage0.0020Vega
Omeros Stock Discussion
Omeros’ Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA
Omeros (OMER) announced successful results from its narsoplimab pivotal trial for treating transplant-associated thrombotic microangiopathy (TA-TMA). The primary statistical analysis showed that patients treated with narsoplimab had an over 3-fold reduction in mortality risk (hazard ratio = 0.32) compared to untreated p...
No comment yet